Document is current
Any future updates will be listed below
-
Authors
Leisman, Daniel E.
Wieruszewski, Patrick M.
Busse, Laurence W.
Chawla, Lakhmir S.
Hibbert, Kathryn A.
Handisides, Damian R.
Khanna, Ashish K.
Ostermann, Marlies
McCurdy, Michael T.
Adams, Christopher D.
Hodges, Tony N.
Bellomo, Rinaldo
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02338843 at ClinicalTrials.govDocuments that mention this clinical trial
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
https://doi.org/10.1186/s13054-023-04446-1
An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock
https://doi.org/10.1186/s13054-025-05311-z
FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock
https://doi.org/10.1007/s40256-018-0297-9
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
https://doi.org/10.1186/s13613-023-01227-5
- License Information
-
More Information
Article History
Received: 30 November 2024
Accepted: 6 February 2025
First Online: 19 February 2025
Declarations
:
: The trial was conducted in accordance with Good Clinical Practice guidelines, applicable local regulations, and Declaration of Helsinki principles. The respective independent institutional review boards reviewed the protocol, informed-consent form, and all other documents before study initiation.
: DEL, LWB, KAH, AKK, MO, and MTC declare no competing interests. RB has received consulting fees from both Innoviva and Viatris as well as research grants from Innoviva. DRH, CDA, and TNH are employees of Innoviva Specialty Therapeutics, Inc., of which La Jolla Pharmaceutical Company is an affiliate. LSC declares that he was formerly an employee of LJPC. PMW is a consultant for Wolters Kluwer/UpToDate and previously received consulting fees from Viatris.
